FDA: Cosmetic Warning Letters Carry Same Weight Regardless Of Issuing Office
This article was originally published in The Rose Sheet
Executive Summary
Around 96% of warning letters for excessive cosmetics claims in 2016 have issued from FDA district offices as opposed to CFSAN headquarters, representing a marked shift from previous years. The agency stresses, however, that the source of a warning letter has no bearing on its implications.
You may also be interested in...
FDA Puts Kibosh On Perfectly Posh For Unapproved Drug Claims
Perfectly Posh, which sells a colorful range of skin, hair and bath products online and through independent social sellers, draws an FDA warning letter for claims about acne, eczema and dandruff treatment, among others.
FDA Targets DermaTox Maker In Year’s First Published Warnings To Cosmetics Firms
Healthy Habits reacts indignantly to FDA’s warning about testimonials for DermaTox products featured on its website, which the agency says identify the items as unapproved drugs. Aegeia Skin Care also receives a warning letter for structure/function and disease-treatment claims on its facial- and body-care products.
FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims
Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.